For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high r ...

For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an ...

Medical Watch Digest for Dec. 9 Acute lymphoblastic leukemia highest survival rate among pediatric cancers Survival rates for ...

Cellectis' strong cash position and pipeline updates boost confidence. See why CLLS stock could benefit from upcoming data in ...

Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease ...

In a recent study published in Nature Cancer, researchers explore treatment resistance and relapse in T-cell acute ...

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...

Ten years after its first FDA approval, Amgen’s Blincyto continues to make inroads in treating acute lymphoblastic leukemia. | Investigators halted study randomization early based on the strong ...

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed ...